Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen-receptor-positive Breast Cancer · Metastatic HER2-Negative Breast Carcinoma · Metastatic Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (Lida A. Mina, M.D.)

Study leads

Lida A. Mina, M.D.
Principal Investigator
Mayo Clinic

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer Female · Breast Cancer · Breast Cancer Metastatic

Abroad (travel likely)RecruitingPHASE2

Boston, United States

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Columbus, United States

Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior

Breast Cancer

Abroad (travel likely)Recruiting

Chapel Hill, United States

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Metastatic Breast Cancer · Stage IV Breast Cancer · Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Basking Ridge, United States · Middletown, United States